Invasive Breast Cancer

Oncology
4
Pipeline Programs
3
Companies
13
Clinical Trials
9 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
375%
Monoclonal Antibody
125%

Competitive Landscape

3 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
PembrolizumabPhase 2Monoclonal Antibody1 trial
Sacituzumab GovitecanPhase 2ADC1 trial
Active Trials
NCT04448886Active Not Recruiting110Est. Jun 2027
NCT04230109Recruiting260Est. Oct 2029
DS
Daiichi SankyoChina - Shanghai
1 program
1
Trastuzumab deruxtecanPhase 2ADC1 trial
Active Trials
NCT05795101Recruiting63Est. Dec 2032
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Trastuzumab deruxtecanPhase 2ADC5 trials
Active Trials
NCT07428044Recruiting14Est. Feb 2027
NCT07124000Recruiting100Est. Mar 2028
NCT06764875Recruiting840Est. Dec 2030
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AstraZenecaTrastuzumab deruxtecan
AstraZenecaTrastuzumab deruxtecan
AstraZenecaTrastuzumab deruxtecan
AstraZenecaTrastuzumab deruxtecan
AstraZenecaTrastuzumab deruxtecan
AstraZenecaTrastuzumab deruxtecan
AstraZenecaTrastuzumab deruxtecan
Daiichi SankyoTrastuzumab deruxtecan
Gilead SciencesPembrolizumab
Gilead SciencesSacituzumab Govitecan
AstraZenecaTrastuzumab deruxtecan
AstraZenecaTrastuzumab deruxtecan
AstraZenecaTrastuzumab deruxtecan

Clinical Trials (13)

Total enrollment: 2,009 patients across 13 trials

NCT06429761AstraZenecaTrastuzumab deruxtecan

Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

Start: Jan 2025Est. completion: Oct 2026100 patients
Phase 4Recruiting
NCT06764875AstraZenecaTrastuzumab deruxtecan

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Start: Mar 2025Est. completion: Dec 2030840 patients
Phase 3Recruiting
NCT07428044AstraZenecaTrastuzumab deruxtecan

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

Start: Feb 2026Est. completion: Feb 202714 patients
Phase 2Recruiting
NCT06533826AstraZenecaTrastuzumab deruxtecan

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Start: Oct 2024Est. completion: Aug 2038357 patients
Phase 2Recruiting
NCT05965479AstraZenecaTrastuzumab deruxtecan

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Start: Apr 2024Est. completion: Apr 202825 patients
Phase 2Recruiting
NCT05744375AstraZenecaTrastuzumab deruxtecan

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

Start: Sep 2023Est. completion: Jul 20252 patients
Phase 2Terminated
NCT05480384AstraZenecaTrastuzumab deruxtecan

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Start: Jul 2023Est. completion: Jan 20261 patients
Phase 2Active Not Recruiting
NCT05795101Daiichi SankyoTrastuzumab deruxtecan

TRUDI: TDXD+Durva in HER2+/Low IBC

Start: May 2023Est. completion: Dec 203263 patients
Phase 2Recruiting
NCT04448886Gilead SciencesPembrolizumab

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Start: Sep 2020Est. completion: Jun 2027110 patients
Phase 2Active Not Recruiting
NCT04230109Gilead SciencesSacituzumab Govitecan

Sacituzumab Govitecan In TNBC

Start: Jul 2020Est. completion: Oct 2029260 patients
Phase 2Recruiting
NCT07124000AstraZenecaTrastuzumab deruxtecan

DESTINY-PANTUMOUR04

Start: Sep 2025Est. completion: Mar 2028100 patients
N/ARecruiting
NCT06727227AstraZenecaTrastuzumab deruxtecan

Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer

Start: Jan 2025Est. completion: Oct 2027135 patients
N/ARecruiting
NCT06231693AstraZenecaTrastuzumab deruxtecan

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

Start: Dec 2023Est. completion: Mar 20242 patients
N/ATerminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 actively recruiting trials targeting 2,009 patients
ADC is the dominant modality (75% of programs)
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)